Mesothelin in solid tumors: biology, biomarker utility, and therapeutic targeting
MSLN is expressed in solid tumor patients, with no differences in expression among histologies. MSLN expression is associated with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage and platinum sensitivity. Higher MSLN expression is detected among primary ovarian cancer patients and correlates with better survival data in HGSOC patients only. According to our data, treatment strategies targeting MSLN should be offered in first line setting rather than in relapse.
Authors
- Ilary Ruscito (ORCID: https://orcid.org/0000-0002-2586-832X)
- Eliane T. Taube (ORCID: https://orcid.org/0000-0003-3041-694X)
- Elena Ioana Braicu (ORCID: https://orcid.org/0000-0001-5357-6001)
- Elizaveta Baisheva
Institutions
- Agostino Gemelli University Polyclinic (IT)
- Humboldt-Universität zu Berlin (DE)
- Stanford Medicine (US)
- Charité - Universitätsmedizin Berlin (DE)
- Stanford University (US)
Publication Details
- Journal
- Current Opinion in Obstetrics & Gynecology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.1097/gco.0000000000001083
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00